Chidamide Combined With Linperlisibon for the Treatment of Refractory/Relapsed Follicular Lymphoma
To observe the safety and efficacy of Chidamide combined with Linperlisib in the treatment of refractory and relapsed follicular lymphoma.
Trial Details
- NCT ID
- NCT06158386
- Phase
- PHASE2
- Sponsor
- The First Affiliated Hospital of Xiamen University
- Status
- RECRUITING
- Cancer Type
- Lymphoma
- Interventions
- Chidamide combined with Linperlisib
- Locations (sample)
- Xiamen, Fujian, China|24.47979,118.08187
Key Eligibility Criteria
- The patients diagnosed with follicular lymphoma with grade 1-3a, have received at least second-line systemic treatment, and at least one of the fir…
- Age ≥18 years old, regardless of gender.
- The estimated survival time is more than 3 months.
- Be able to follow the requirements of the research plan.
For full eligibility, visit ClinicalTrials.gov.
Check If You May Be Eligible
Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.
Find Lymphoma Trials on Trialify →